Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Philogen SpA (IT:PHIL)
MILAN:PHIL
Holding IT:PHIL?
Track your performance easily
PHIL Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€15.70 - €21.90
Previous Close€21.1
Volume3.70K
Average Volume (3M)5.67K
Market Cap
€617.02M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Sep 25, 2024EPS Estimate
-€0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares OutstandingN/A
10 Day Avg. Volume3,972
30 Day Avg. Volume5,666
Standard Deviation0.04
R-Squared0.04
Alpha-0.00857
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)25.77
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.00Price Target Upside18.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialFinal data from the P3 trial of neoadjuvant Nidlegy in locally advanced resectable melanoma confirm the superiority of Nidlegy vs. surgery alone.
Financial ForecastsTaking into account the expanded laBCC population, peak sales for Nidlegy in NMSC are now projected to reach €1.8bn, reflecting a significant upward revision from previous estimates.
Strategic PartnershipsPreparations for commercialisation are underway with partner Sun Pharma, enhancing the market reach and support for Nidlegy post-approval.
Bears Say
Drug Safety ConcernsPatients in the Nidlegy arm experienced more treatment-related adverse events.
Financial HealthPhilogen’s net cash position has decreased by 9.4%.
Product Launch DelaysFollowing the announced strategic change in the development of Nidlegy in NMSC, there is an expected delay in laSCC launch and a two-year delay in laBCC launch.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.16% Other Institutional Investors
99.84% Public Companies and
Individual Investors
PHIL FAQ
What was Philogen SpA’s price range in the past 12 months?
Philogen SpA lowest stock price was €15.70 and its highest was €21.90 in the past 12 months.
What is Philogen SpA’s market cap?
Currently, no data Available
When is Philogen SpA’s upcoming earnings report date?
Philogen SpA’s upcoming earnings report date is Sep 25, 2024 which is in 17 days.
How were Philogen SpA’s earnings last quarter?
Currently, no data Available
Is Philogen SpA overvalued?
According to Wall Street analysts Philogen SpA’s price is currently Undervalued.
Does Philogen SpA pay dividends?
Philogen SpA does not currently pay dividends.
What is Philogen SpA’s EPS estimate?
Philogen SpA’s EPS estimate is -€0.32.
How many shares outstanding does Philogen SpA have?
Philogen SpA has 29,242,860 shares outstanding.
What happened to Philogen SpA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Philogen SpA?
Currently, no hedge funds are holding shares in IT:PHIL
---
Philogen SpA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.39%
12-Months-Change
Fundamentals
Return on Equity
-6.54%
Trailing 12-Months
Asset Growth
-5.21%
Trailing 12-Months
Company Description
Philogen SpA
Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others.
---
PHIL Stock 12 Month Forecast
Average Price Target
€25.00
▲(18.48% Upside)
Technical Analysis
Best Analysts Covering PHIL
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+22.53%
reiterated a buy rating 5 months ago
Copying Rajan Sharma's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.53% per trade.
---